For Plaque Psoriasis In Patients 12+

In Clinical Trials,

45% of patients were cleared or almost cleared in 2 weeks.1

The Burden of Psoriasis goes beyond physical discomfort5

Symptoms such as plaques, scaling, and itching impact both physical and social aspects of patients’ lives.5,6

Patients often try to hide unsightly redness, scaling, and plaques.6

Itching and physical pain can disrupt daily tasks as well as social events and activities.6

For patients living with the burden of psoriasis, every day waiting for relief is a day too long.

When Patients Need Class 1 Clearance ASAP7

In clinical trials, 45% of patients were cleared or almost cleared in 2 weeks.1
See the Data

See the 2-week difference

ULTRAVATE® Lotion can be used to treat plaque psoriasis affecting elbows, knees, and large body surface areas.
See the results

Efficacy + Moisturization

ULTRAVATE® Lotion provides the hydrating benefits of a cream.3
See the Data

Patient Savings

Help your commercially insured patients pay less for their ULTRAVATE® Lotion prescriptions.
Learn More
References: 1. ULTRAVATE® Lotion [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2020. 2. National Psoriasis Foundation. Topical steroid potency chart. https:// Accessed September 25, 2020. 3. Grove G, Zerweck C, Houser T, Andrasfay A, Gauthier B, Holland C, Piacquadio D. Halobetasol Propionate Lotion, 0.05% Provides Superior Hydration Compared to Halobetasol Propionate Cream, 0.05% in a Double-Blinded Study of Occlusivity and Hydration. J Drugs Dermatol. 2017 Feb 1;16(2):140-144. PMID: 28300856. 4. Sun Pharmaceutical Industries, Inc. Data on file. 2020. 5. Zschocke I, Mrowietz U, Karakasili E, Reich K. Non-adherence and measures to improve adherence in the topical treatment of psoriasis. J Eur Acad Dermatol Venereol. 2014;28:4-9. 6. Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003–2011. PLoS One. 2012;7(12):e52935. doi:10.1371/journal.pone.0052935. 7. Uva L, Miguel D, Pinheiro C, et al. Mechanisms of Action of Topical Corticosteroids in Psoriasis. International Journal of Endocrinology. November 20, 2012. Accessed December 9, 2020. 8. Stoughton RB. Are generic formulations equivalent to trade name topical glucocorticosteroids? Arch Dermatol. 1987;123(10):1312-4.

ULTRAVATE (halobetasol propionate) Lotion is a corticosteroid indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older.


Usage: Limit use to 50 g/week. Discontinue treatment when control is achieved. If no improvement is seen within 2 weeks, reassess diagnosis. Treatment beyond 2 consecutive weeks is not recommended. Avoid use on the face, scalp, groin, or axillae.

Effects on Endocrine System: Reversible hypothalamic-pituitary-adrenal (HPA) axis suppression may occur, with the potential for glucocorticosteroid insufficiency during or after treatment. Systemic effects of topical corticosteroids may also include Cushing’s syndrome, hyperglycemia, and glucosuria. Systemic absorption may require evaluation for HPA axis suppression. Use of potent corticosteroids on large areas, for prolonged durations, under occlusive dressings, or on an altered skin barrier may increase systemic exposure. Children may be more susceptible to systemic toxicity when treated with topical steroids.

Local Adverse Reactions: Local adverse reactions with topical steroids may include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection and miliaria. These may be more likely to occur with occlusive use, prolonged use or more potent corticosteroids, including ULTRAVATE.

Concomitant Skin Infections: Use an appropriate antimicrobial agent if a skin infection is present or develops.

Allergic Contact Dermatitis: Discontinue ULTRAVATE Lotion if allergic contact dermatitis is established.

In clinical trials the most common adverse reactions (≥1%) were telangiectasia, application site atrophy, and headache.

To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc. at 1-800-406-7984 or FDA at 1-800-FDA-1088 or

Please see Full Prescribing Information for complete prescribing details.